EP3243505A1 — A pharmaceutical composition comprising amorphous apixaban
Assigned to Zaklady Farmaceutyczne Polpharma SA · Expires 2017-11-15 · 9y expired
What this patent protects
The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of apixaban or a salt thereof together with one or more pharmaceutically acceptable excipients or carriers, wherein apixaban is amorphous and the composition exhibits an in…
USPTO Abstract
The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of apixaban or a salt thereof together with one or more pharmaceutically acceptable excipients or carriers, wherein apixaban is amorphous and the composition exhibits an in vitro dissolution profile measured in phosphate buffer at pH 6.8 containing 0.05 % weight/volume of sodium lauryl sulfate according to which: at least 30% of apixaban is dissolved after 5 minutes and at least 60% of apixaban is dissolved after 10 minutes; processes for its preparation and its use for the treatment of thromboembolic diseases or disorders.
Drugs covered by this patent
- Eliquis (apixaban) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.